Qing Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Qing Xia has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Andrew J. Palmer
Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia
7 shared publications David Brain
Australian Centre for Health Services Innovation (AusHSI) and Centre for Healthcare Transformation, School of Public Health & Social Work, Queensland University of Technology (QUT), Brisbane, Queensland, Australia
5 shared publicationsHannah Carter
5 shared publicationsBarbara de Graaff
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
4 shared publicationsHannah E. Carter
Australian Centre for Health Services Innovation (AusHSI) and Centre for Healthcare Transformation, School of Public Health & Social Work, Queensland University of Technology (QUT)
4 shared publicationsJulie A. Campbell
Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
4 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by Springer Nature in Research Square
Are Semaglutide and Tirzepatide Cost-Effective for Weight Management? A Systematic Review and Meta-analysis
The clinical effectiveness of semaglutide and tirzepatide for weight management has been well established; however, their cost-effectiveness remains uncertain. This study aims to systematically synthesise cost-effectiveness evidence for both agonists for weight management in individuals without diabetes, compared to any possible alternatives. PubMed, Embase, MEDLINE and Scopus were searched to retrieve eligible studies. Basic study characteristics, model characteristics/inputs/results were extracted. Base-case cost-effectiveness outcomes were classified as ‘dominant’, ‘cost-effective’, or ‘not cost-effective’ based on each study’s willingness-to-pay threshold. Subgroup analyses stratified by target population, treatment duration, comparator type, and sponsor type. Sensitivity analyses considered standardising costs and applying various WTP thresholds. N=34 articles (with 76 comparisons for semaglutide and 37 for tirzepatide) were included, mostly from high-income settings and from a healthcare payer perspective.Overall, semaglutide and tirzepatide were not cost-effective in 63% and 57% of comparisons, respectively. Favorable outcomes were generally observed in comparisons modelling short-term treatment. Notably, in comparisons sponsored by the respective manufacturers, both agonists were found to be either dominant or cost-effective, while dominated outcomes were only reported in comparisons without industry involvement. Additionally, both agonists were more likely to be cost-effective among populations with weight-related comorbidities. Findings remained consistent in sensitivity analyses. Current evidence did not consistently support semaglutide or tirzepatide as cost-effective interventions for weight management, particularly in the absence of robust long-term clinical data. Future independent economic evaluations with long-term clinical evidence are needed to identify the subpopulations most likely derive value from GLP-1RA therapy.
- 18 May 2026
- Published by Springer Nature in Research Square
Open AccessAre Semaglutide and Tirzepatide Cost-Effective for Weight Management? A Systematic Review and Meta-analysis
The clinical effectiveness of semaglutide and tirzepatide for weight management has been well established; however, their cost-effectiveness remains uncertain. This study aims to systematically synthesise cost-effectiveness evidence for both agonists for weight management in individuals without diabetes, compared to any possible alternatives. PubMed, Embase, MEDLINE and Scopus were searched to retrieve eligible studies. Basic study characteristics, model characteristics/inputs/results were extracted. Base-case cost-effectiveness outcomes were classified as ‘dominant’, ‘cost-effective’, or ‘not cost-effective’ based on each study’s willingness-to-pay threshold. Subgroup analyses stratified by target population, treatment duration, comparator type, and sponsor type. Sensitivity analyses considered standardising costs and applying various WTP thresholds. N=34 articles (with 76 comparisons for semaglutide and 37 for tirzepatide) were included, mostly from high-income settings and from a healthcare payer perspective.Overall, semaglutide and tirzepatide were not cost-effective in 63% and 57% of comparisons, respectively. Favorable outcomes were generally observed in comparisons modelling short-term treatment. Notably, in comparisons sponsored by the respective manufacturers, both agonists were found to be either dominant or cost-effective, while dominated outcomes were only reported in comparisons without industry involvement. Additionally, both agonists were more likely to be cost-effective among populations with weight-related comorbidities. Findings remained consistent in sensitivity analyses. Current evidence did not consistently support semaglutide or tirzepatide as cost-effective interventions for weight management, particularly in the absence of robust long-term clinical data. Future independent economic evaluations with long-term clinical evidence are needed to identify the subpopulations most likely derive value from GLP-1RA therapy.
- Open Access
Adverse Events and Associated Economic Burden of COVID-19 Vaccination in Queensland, Australia: Findings from the Cross-Sectional QoVAX-Statewide Study
Background/Objectives: The economic impact of adverse events following COVID-19 immunisation (AEFIs) in Australia is underexplored. This study aimed to assess the economic burden of AEFIs on both healthcare systems and societal productivity. Methods: A cross-sectional survey was conducted in Queensland residents aged ≥18 years who had received at least one dose of a COVID-19 vaccine in the preceding 12 months. Overall, 6964 participants were recruited from July to September 2022 via email and broad social media campaigns. The survey collected data on the incidence, type and duration of AEFIs; healthcare utilisation; and work-related absenteeism. Healthcare costs were estimated using national healthcare reimbursement data, and productivity costs were estimated using Australian Bureau of Statistics Average Weekly Earnings. Results: Of the 6797 eligible respondents (predominantly female [62%]; median age: 52 years), AEFIs were reported by 53.4%, 44.1%, 40.7%, and 40.9% following doses 1 to 4, respectively. Pain and tenderness were predominant local AEFIs, while tiredness and headaches were the most frequent systemic AEFIs, generally resolving within three days. Relatively few participants reporting AEFIs consulted medical professionals: 7.0%, 7.3%, 5.1%, and 1.9% following each dose, respectively. The mean healthcare cost per person reporting AEFIs was AUD 24, AUD 88, AUD 22, and AUD 4 following each respective dose. Work absenteeism was recorded in 16.5%, 18.2%, 15.2%, and 11.2% following each dose with mean absenteeism days per person of 4.7, 7.4, 3.6 and 2.1, respectively, and mean productivity costs per person reporting AEFIs amounting to AUD 1494, AUD 2388, AUD 1136, and AUD 690, respectively. Conclusions: Participants reported mostly mild AEFIs with only a small proportion of individuals seeking medical services. Productivity costs attributable to these AEFIs exceeded direct healthcare expenses incurred.
Open AccessAdverse Events and Associated Economic Burden of COVID-19 Vaccination in Queensland, Australia: Findings from the Cross-Sectional QoVAX-Statewide Study
Background/Objectives: The economic impact of adverse events following COVID-19 immunisation (AEFIs) in Australia is underexplored. This study aimed to assess the economic burden of AEFIs on both healthcare systems and societal productivity. Methods: A cross-sectional survey was conducted in Queensland residents aged ≥18 years who had received at least one dose of a COVID-19 vaccine in the preceding 12 months. Overall, 6964 participants were recruited from July to September 2022 via email and broad social media campaigns. The survey collected data on the incidence, type and duration of AEFIs; healthcare utilisation; and work-related absenteeism. Healthcare costs were estimated using national healthcare reimbursement data, and productivity costs were estimated using Australian Bureau of Statistics Average Weekly Earnings. Results: Of the 6797 eligible respondents (predominantly female [62%]; median age: 52 years), AEFIs were reported by 53.4%, 44.1%, 40.7%, and 40.9% following doses 1 to 4, respectively. Pain and tenderness were predominant local AEFIs, while tiredness and headaches were the most frequent systemic AEFIs, generally resolving within three days. Relatively few participants reporting AEFIs consulted medical professionals: 7.0%, 7.3%, 5.1%, and 1.9% following each dose, respectively. The mean healthcare cost per person reporting AEFIs was AUD 24, AUD 88, AUD 22, and AUD 4 following each respective dose. Work absenteeism was recorded in 16.5%, 18.2%, 15.2%, and 11.2% following each dose with mean absenteeism days per person of 4.7, 7.4, 3.6 and 2.1, respectively, and mean productivity costs per person reporting AEFIs amounting to AUD 1494, AUD 2388, AUD 1136, and AUD 690, respectively. Conclusions: Participants reported mostly mild AEFIs with only a small proportion of individuals seeking medical services. Productivity costs attributable to these AEFIs exceeded direct healthcare expenses incurred.
- 20 May 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (6) , 1032-1041
Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis
BACKGROUND: Significant clinical efficacy has been shown for semaglutide in managing type 2 diabetes (T2D); however, its cost-effectiveness remains uncertain. PURPOSE: To systematically review existing evidence on cost-effectiveness of semaglutide versus other T2D medications. DATA SOURCES: PubMed, Embase, and the Cost-Effectiveness Analysis Registry (by 11 June 2024). STUDY SELECTION: A total of 45 articles (with 119 comparisons) from 2019 onward were included, representing Europe (n = 24), North America (n = 13), and Asia (all from China) (n = 8). DATA EXTRACTION: Study characteristics and model characteristics/inputs/results were extracted. Lifetime costs and quality-adjusted life-years were evaluated. Proportions for cost-effectiveness outcomes (dominant, cost-effective, not cost-effective) were calculated. Subgroup analyses by region, sponsor type, comparator type, and model assumptions were performed. In sensitivity analysis a standard willingness-to-pay threshold was applied. DATA SYNTHESIS: Of the articles included, 93.3% included adoption of a lifetime horizon and 84.4% a health care perspective and 68.9% were industry sponsored. For most studies reporting quality was high (86.7%). Overall, semaglutide was dominant/cost-effective in 73.9% of all comparisons. Notably, semaglutide was found to be dominant/cost-effective in all comparisons sponsored by Novo Nordisk versus in 50.0% of these funded by nonindustry sponsors and in none funded by other industry sponsors. Additionally, semaglutide was more cost-effective in high-income countries and in studies with adoption of a broader perspective, longer horizon, and lower discount rates. Results remained consistent with conversion with a common currency unit and willingness-to-pay threshold of US$50,000. LIMITATIONS: Less detailed demographic information for more granular analyses. CONCLUSIONS: Semaglutide is generally cost-effective compared with other glucose-lowering medications in evaluation against within-study willingness-to-pay thresholds; however, results varied by study sponsor type, region, and model assumptions, highlighting the need for transparent and context-sensitive economic evaluations.
- 20 May 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (6) , 1032-1041
Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis
BACKGROUND: Significant clinical efficacy has been shown for semaglutide in managing type 2 diabetes (T2D); however, its cost-effectiveness remains uncertain. PURPOSE: To systematically review existing evidence on cost-effectiveness of semaglutide versus other T2D medications. DATA SOURCES: PubMed, Embase, and the Cost-Effectiveness Analysis Registry (by 11 June 2024). STUDY SELECTION: A total of 45 articles (with 119 comparisons) from 2019 onward were included, representing Europe (n = 24), North America (n = 13), and Asia (all from China) (n = 8). DATA EXTRACTION: Study characteristics and model characteristics/inputs/results were extracted. Lifetime costs and quality-adjusted life-years were evaluated. Proportions for cost-effectiveness outcomes (dominant, cost-effective, not cost-effective) were calculated. Subgroup analyses by region, sponsor type, comparator type, and model assumptions were performed. In sensitivity analysis a standard willingness-to-pay threshold was applied. DATA SYNTHESIS: Of the articles included, 93.3% included adoption of a lifetime horizon and 84.4% a health care perspective and 68.9% were industry sponsored. For most studies reporting quality was high (86.7%). Overall, semaglutide was dominant/cost-effective in 73.9% of all comparisons. Notably, semaglutide was found to be dominant/cost-effective in all comparisons sponsored by Novo Nordisk versus in 50.0% of these funded by nonindustry sponsors and in none funded by other industry sponsors. Additionally, semaglutide was more cost-effective in high-income countries and in studies with adoption of a broader perspective, longer horizon, and lower discount rates. Results remained consistent with conversion with a common currency unit and willingness-to-pay threshold of US$50,000. LIMITATIONS: Less detailed demographic information for more granular analyses. CONCLUSIONS: Semaglutide is generally cost-effective compared with other glucose-lowering medications in evaluation against within-study willingness-to-pay thresholds; however, results varied by study sponsor type, region, and model assumptions, highlighting the need for transparent and context-sensitive economic evaluations.
- Open Access
- 10 April 2025
- Published by Elsevier in Health Policy
- Vol. 156, 105319
Growth and changing landscape of the cost-utility literature: an Australian perspective, 1992-2022
- 10 April 2025
- Published by Elsevier in Health Policy
- Vol. 156, 105319
Open AccessGrowth and changing landscape of the cost-utility literature: an Australian perspective, 1992-2022
- Open Access
- 4 February 2025
- Published by Center for Open Science in OSF Preprints
The Impacts of Bariatric Surgery on Productivity and Employment Status: A Comprehensive Systematic Review
Importance: Bariatric surgery is widely recognised for its health benefits; however, its association with work productivity and employment rates, though frequently reported, has not been systematically synthesised. This evidence is crucial to inform the economic evaluation of bariatric surgery.Objective: To systematically analyse the evidence on occupational outcomes of bariatric surgery.Evidence Review: A systematic literature search was conducted in five online databases to identify empirical studies on bariatric surgery-related employment and productivity outcomes published up to April 2024. Two co-authors independently screened the literature, and all co-authors contributed to data extraction and validation. Occupational outcomes were compared between “before vs. after” surgery or the differences between “surgery vs. non-surgery”. Comparisons were categorised into three groups: “improvement”, “no differences”, and “worse”. Where possible, summary values of occupational outcomes (e.g., the average employment rate) were synthesised for each observational time point. Reported barriers and enablers to employment return or productivity were also identified. Findings: A total of 42 studies from 15 countries were included. Studies were published between 1977 and 2023, with most conducted in high-income countries. Roux-en-Y Gastric Bypass (RYGB) was the most frequently studied procedure. The most commonly evaluated metrics were (un)employment rates and absenteeism/sick leave. Bariatric surgery was associated with improvements in presenteeism and work hours/ability, and short-term absenteeism and employment rates. However, the long-term employment rate followed a reversed U-shape trajectory, with employment rates initially increasing post-surgery but returning to baseline levels after about five years. Key barriers to improved occupational outcomes included insufficient weight loss, female gender, older age, preoperative comorbidities, lower quality of life, and a lack of prior work experience.Conclusions and Relevance: Bariatric surgery demonstrates positive short-term impacts on productivity and employment, but its long-term occupational benefits remain uncertain. Certain subgroups, such as females and older adults, may require tailored post-surgery support to sustain employment and productivity gains. These findings highlight the critical need for long-term strategies to sustain the occupational benefits post-surgery and to develop targeted interventions for at-risk populations.
- 4 February 2025
- Published by Center for Open Science in OSF Preprints
Open AccessThe Impacts of Bariatric Surgery on Productivity and Employment Status: A Comprehensive Systematic Review
Importance: Bariatric surgery is widely recognised for its health benefits; however, its association with work productivity and employment rates, though frequently reported, has not been systematically synthesised. This evidence is crucial to inform the economic evaluation of bariatric surgery.Objective: To systematically analyse the evidence on occupational outcomes of bariatric surgery.Evidence Review: A systematic literature search was conducted in five online databases to identify empirical studies on bariatric surgery-related employment and productivity outcomes published up to April 2024. Two co-authors independently screened the literature, and all co-authors contributed to data extraction and validation. Occupational outcomes were compared between “before vs. after” surgery or the differences between “surgery vs. non-surgery”. Comparisons were categorised into three groups: “improvement”, “no differences”, and “worse”. Where possible, summary values of occupational outcomes (e.g., the average employment rate) were synthesised for each observational time point. Reported barriers and enablers to employment return or productivity were also identified. Findings: A total of 42 studies from 15 countries were included. Studies were published between 1977 and 2023, with most conducted in high-income countries. Roux-en-Y Gastric Bypass (RYGB) was the most frequently studied procedure. The most commonly evaluated metrics were (un)employment rates and absenteeism/sick leave. Bariatric surgery was associated with improvements in presenteeism and work hours/ability, and short-term absenteeism and employment rates. However, the long-term employment rate followed a reversed U-shape trajectory, with employment rates initially increasing post-surgery but returning to baseline levels after about five years. Key barriers to improved occupational outcomes included insufficient weight loss, female gender, older age, preoperative comorbidities, lower quality of life, and a lack of prior work experience.Conclusions and Relevance: Bariatric surgery demonstrates positive short-term impacts on productivity and employment, but its long-term occupational benefits remain uncertain. Certain subgroups, such as females and older adults, may require tailored post-surgery support to sustain employment and productivity gains. These findings highlight the critical need for long-term strategies to sustain the occupational benefits post-surgery and to develop targeted interventions for at-risk populations.
- Open Access
- 2 December 2024
- Published by Center for Open Science in OSF Preprints
Growth and Changing Landscape of the Cost-Utility Literature: An Australian Perspective, 1992-2022
Objectives: To provide a comprehensive overview of the volume, trends, and characteristics of the use of cost utility analysis (CUA) in healthcare decision making in Australia.Design and setting: Bibliometric analysis of published studies on CUA identified from the Cost-Effectiveness Analysis Registry, a comprehensive source of CUA data, between 1992-2022. Main outcome measures: Australian-based CUAs using cost-per-quality adjusted life years (QALYs) or cost-per-disability adjusted life years (DALYs) as the outcome, as well as the trends and relevant characteristics of the CUAs.Data synthesis: A total of 488 unique Australian-based CUAs were analysed (cost-per-QALY: n=398; cost-per-DALY: n=90). Over the last three decades, the volume and quality of CUAs in Australia have steadily increased. Interventions that were frequently evaluated were on pharmaceuticals (21.7%), health education/behaviour (18.0%), and models of care (16.7%), while diseases of the circulatory system, cancers, and metabolic diseases were the most studies health conditions. Most CUAs (72.7%) were conducted from a healthcare payer perspective, with only 19.0% adopting a broader societal perspective. A 5% discount rate applied in about half of studies. Half (50.6%) of the studies used a $50,000 WTP threshold, followed distantly by thresholds between $28,001-$49,999 (5.3%) or $28,000 (3.9%). Most studies were funded by academic/government sources (61.7%), while 14.5% were supported by the pharmaceutical or medical device industry. Overall, 60.2% of QALY studies reported an ICER less than $28,000, and 71.5% less than $50,000, resulting in a 11.3% gap. For DALY studies, there was a 12.3% gap (74.1% - 61.8%) in the proportions reporting ICERS between threshold of $28,000 and $50,000. Conclusions: The increasing volume of CUAs underscores the importance of efficient allocation of scare resources in the Australian health system. However, gaps remain in standardised reporting and reevaluating the alignment of discount rates and WTP thresholds with international standards, which require further research for more equitable healthcare resource allocation.
- 2 December 2024
- Published by Center for Open Science in OSF Preprints
Open AccessGrowth and Changing Landscape of the Cost-Utility Literature: An Australian Perspective, 1992-2022
Objectives: To provide a comprehensive overview of the volume, trends, and characteristics of the use of cost utility analysis (CUA) in healthcare decision making in Australia.Design and setting: Bibliometric analysis of published studies on CUA identified from the Cost-Effectiveness Analysis Registry, a comprehensive source of CUA data, between 1992-2022. Main outcome measures: Australian-based CUAs using cost-per-quality adjusted life years (QALYs) or cost-per-disability adjusted life years (DALYs) as the outcome, as well as the trends and relevant characteristics of the CUAs.Data synthesis: A total of 488 unique Australian-based CUAs were analysed (cost-per-QALY: n=398; cost-per-DALY: n=90). Over the last three decades, the volume and quality of CUAs in Australia have steadily increased. Interventions that were frequently evaluated were on pharmaceuticals (21.7%), health education/behaviour (18.0%), and models of care (16.7%), while diseases of the circulatory system, cancers, and metabolic diseases were the most studies health conditions. Most CUAs (72.7%) were conducted from a healthcare payer perspective, with only 19.0% adopting a broader societal perspective. A 5% discount rate applied in about half of studies. Half (50.6%) of the studies used a $50,000 WTP threshold, followed distantly by thresholds between $28,001-$49,999 (5.3%) or $28,000 (3.9%). Most studies were funded by academic/government sources (61.7%), while 14.5% were supported by the pharmaceutical or medical device industry. Overall, 60.2% of QALY studies reported an ICER less than $28,000, and 71.5% less than $50,000, resulting in a 11.3% gap. For DALY studies, there was a 12.3% gap (74.1% - 61.8%) in the proportions reporting ICERS between threshold of $28,000 and $50,000. Conclusions: The increasing volume of CUAs underscores the importance of efficient allocation of scare resources in the Australian health system. However, gaps remain in standardised reporting and reevaluating the alignment of discount rates and WTP thresholds with international standards, which require further research for more equitable healthcare resource allocation.
- 21 November 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (12) , 4413-4424
Economic Impact of Bariatric Surgery in Australia: 16-Year Results from the 45 and Up Study with Linked Health Data
Background Bariatric surgery is the most effective long-term therapy for severe obesity; however, empirical investigation of its economic impacts has been based on limited samples, short-term costs, and a narrow range of cost categories. This study aimed to evaluate the economic impacts of bariatric surgery in a large cohort of Australians aged ≥ 45 years. Methods N = 1157 operated (surgery) and 1157 non-operated participants were selected from the 45 and Up Study. Data sources included the baseline and follow-up surveys along with linked state and national administrative health datasets. Linear mixed-effects regression predicted the cost trajectory 8 years pre- and post-bariatric surgery, and the difference-in-differences approach evaluated its economic impact. Sensitivity analyses included an approximation of indirect costs and subgroup analysis by surgery type. Results The matched cohort composed 77% female, had an average age of 58.1 ± 5.8 years. Direct healthcare costs increased over time in both groups. Costs for the operated group peaked ($15,884) during the surgery year and became up to 23.8% lower than those for the non-operated group from the second year post-surgery when including indirect costs. Surgery’s economic benefits increased over longer horizons, with a maximum annual cost-saving of $3196 per person in the eighth post-surgery year. However, even after accounting for indirect costs, cumulative cost-savings were not achieved. Subgroup analysis revealed sleeve gastrectomy as the least costly surgical option. Conclusion Higher short-term costs in the surgery year primarily drove inter-group cost differences. The economic value of bariatric surgery lies in the long-term benefits, particularly when considering indirect costs. Graphical Abstract
- 21 November 2024
- Published by Springer Nature in Obesity Surgery
- Vol. 34 (12) , 4413-4424
Economic Impact of Bariatric Surgery in Australia: 16-Year Results from the 45 and Up Study with Linked Health Data
Background Bariatric surgery is the most effective long-term therapy for severe obesity; however, empirical investigation of its economic impacts has been based on limited samples, short-term costs, and a narrow range of cost categories. This study aimed to evaluate the economic impacts of bariatric surgery in a large cohort of Australians aged ≥ 45 years. Methods N = 1157 operated (surgery) and 1157 non-operated participants were selected from the 45 and Up Study. Data sources included the baseline and follow-up surveys along with linked state and national administrative health datasets. Linear mixed-effects regression predicted the cost trajectory 8 years pre- and post-bariatric surgery, and the difference-in-differences approach evaluated its economic impact. Sensitivity analyses included an approximation of indirect costs and subgroup analysis by surgery type. Results The matched cohort composed 77% female, had an average age of 58.1 ± 5.8 years. Direct healthcare costs increased over time in both groups. Costs for the operated group peaked ($15,884) during the surgery year and became up to 23.8% lower than those for the non-operated group from the second year post-surgery when including indirect costs. Surgery’s economic benefits increased over longer horizons, with a maximum annual cost-saving of $3196 per person in the eighth post-surgery year. However, even after accounting for indirect costs, cumulative cost-savings were not achieved. Subgroup analysis revealed sleeve gastrectomy as the least costly surgical option. Conclusion Higher short-term costs in the surgery year primarily drove inter-group cost differences. The economic value of bariatric surgery lies in the long-term benefits, particularly when considering indirect costs. Graphical Abstract
- Open Access
- 6 November 2024
- Published by Center for Open Science in OSF Preprints
Adverse Events and Associated Economic Burden of COVID-19 Vaccination in Queensland, Australia: findings from the cross-sectional QoVAX-Statewide study
Objective: To assess the economic burden on both healthcare system and societal productivity associated with AEFIs following COVID-19 vaccines in Australia.Design, Setting, and Participants: A cross-sectional survey was conducted in the general population aged ≥18 years in Queensland, Australia, who had received a COVID-19 vaccine in the preceding 12 months. N=6,964 participants were recruited between 1 July and 30 September 2022 via email and a broad social media campaign.Exposures: At least one dose of any available COVID-19 vaccines.Main outcomes and measures: Incidence and duration of local and systemic AEFIs; healthcare utilisation and expenditures; and the productivity losses and costs due to AEFIs. Healthcare costs were estimated using Australian national public healthcare reimbursement data, and productivity costs using Australian Bureau of Statistics Average Weekly Earnings.Results: Of 6,797 eligible respondents, 6,777 (99.7%) received at least one dose, 6,747 (99.3%) at least two doses, 6,268 (92.2%) at least three doses, and 3,084 (45.4%) at least four doses. AEFIs were reported by 53.4%, 44.1%, 40.7%, and 40.9% following Doses 1 to 4, respectively. Pain and tenderness were predominant local AEFIs, while tiredness and headaches were the most frequent systemic AEFIs, generally resolving within three days. A decline in AEFI rates was noted across successive doses. Relatively few participants reporting AEFIs consulted medical professionals: 7.0%, 7.3%, 5.1%, and 1.9% following each dose respectively. The mean healthcare cost per person reporting AEFIs was $24, $88, $22, and $4 following each respective dose. Work absenteeism was recorded in 16.5%, 18.2%, 15.2%, and 11.2% following each dose, with mean absenteeism days per person of 4.7, 7.4, 3.6 and 2.1, respectively, and mean productivity costs per person reporting AEFIs amounting to $1494, $2388, $1136, and $690, respectively.Conclusions: Participants reported mostly mild AEFIs, with only a small proportion of individuals seeking medical services. The productivity costs attributable to these AEFIs were substantially greater than the direct healthcare expenses incurred.
- 6 November 2024
- Published by Center for Open Science in OSF Preprints
Open AccessAdverse Events and Associated Economic Burden of COVID-19 Vaccination in Queensland, Australia: findings from the cross-sectional QoVAX-Statewide study
Objective: To assess the economic burden on both healthcare system and societal productivity associated with AEFIs following COVID-19 vaccines in Australia.Design, Setting, and Participants: A cross-sectional survey was conducted in the general population aged ≥18 years in Queensland, Australia, who had received a COVID-19 vaccine in the preceding 12 months. N=6,964 participants were recruited between 1 July and 30 September 2022 via email and a broad social media campaign.Exposures: At least one dose of any available COVID-19 vaccines.Main outcomes and measures: Incidence and duration of local and systemic AEFIs; healthcare utilisation and expenditures; and the productivity losses and costs due to AEFIs. Healthcare costs were estimated using Australian national public healthcare reimbursement data, and productivity costs using Australian Bureau of Statistics Average Weekly Earnings.Results: Of 6,797 eligible respondents, 6,777 (99.7%) received at least one dose, 6,747 (99.3%) at least two doses, 6,268 (92.2%) at least three doses, and 3,084 (45.4%) at least four doses. AEFIs were reported by 53.4%, 44.1%, 40.7%, and 40.9% following Doses 1 to 4, respectively. Pain and tenderness were predominant local AEFIs, while tiredness and headaches were the most frequent systemic AEFIs, generally resolving within three days. A decline in AEFI rates was noted across successive doses. Relatively few participants reporting AEFIs consulted medical professionals: 7.0%, 7.3%, 5.1%, and 1.9% following each dose respectively. The mean healthcare cost per person reporting AEFIs was $24, $88, $22, and $4 following each respective dose. Work absenteeism was recorded in 16.5%, 18.2%, 15.2%, and 11.2% following each dose, with mean absenteeism days per person of 4.7, 7.4, 3.6 and 2.1, respectively, and mean productivity costs per person reporting AEFIs amounting to $1494, $2388, $1136, and $690, respectively.Conclusions: Participants reported mostly mild AEFIs, with only a small proportion of individuals seeking medical services. The productivity costs attributable to these AEFIs were substantially greater than the direct healthcare expenses incurred.
- Open Access
- 4 October 2024
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (1) , 62.e15-62.e26
Cost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia
- 4 October 2024
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (1) , 62.e15-62.e26
Open AccessCost-effectiveness analysis of microwave ablation versus robot-assisted partial nephrectomy for patients with small renal masses in Australia